

The World Generic Market Report 2012

Volume I: Global Overview and Company Profiles



World Leaders in Health Industry Analysis



The World Generic Market Report 2012

ISBN: 978-1-85822-441-1

© Copyright 2012 Espicom Business Intelligence Publications Limited

All rights reserved. No part of this publication may be reproduced or used in any form or by any means graphic, electronic or mechanical, including photocopying, recording, taping or storage in information retrieval systems without the express permission of the publisher.

Every care has been taken to ensure that the information contained in this report is correct. The publisher accepts no liability for decisions made on the basis of information contained

British Library Cataloguing in Publication Data.

A catalogue record for this report is available from the British Library.

TABLE OF CONTENTS

FOREWORD	xvii
The state of the Industry	1
Generic Consolidations, Mergers and Acquisitions	1
Generic and Branded Acquisitions and Agreements.....	3
The branded industry's 'patent cliff'	4
Major Generic Manufacturers	5
Biosimilars	8
In the USA.....	8
Another option: file a full BLA?	9
The development of a US biosimilar pathway	9
The BCPIA.....	10
Implementation of the BCPIA	11
<i>FDA guidance documents published</i>	<i>13</i>
FDA sends user fee scheme to Congress.....	14
In Europe	14
EMA Guideline Documents.....	15
Regulation of Monoclonal Antibodies	17
Elsewhere	17
Market acceptance.....	17
Positive drivers for biosimilar acceptance.....	18
Potential barriers to entry for biosimilars	18
Who will the developers be?	18
Current Issues in the USA.....	19
Authorised generics	19
FDA issues direct final rule regarding listing of authorised generics	20
Reverse Payments.....	21
Shared exclusivity	21
GDUFA	25
FDA Inspections and Warning Letters.....	25
Impax Laboratories	26
Aurobindo Pharma.....	26
Dr Reddy's Laboratories	26
Ranbaxy Laboratories consent decree	27
Current Issues in the European Union.....	28
EC releases final report into pharmaceutical sector.....	28
Monitoring of patent settlements.....	30

EC carries out surprise inspections at pharmaceutical firms	31
Generic drug shipments seized in the EU	32
Canada – EU Comprehensive Economic and Trade Agreement	33
The WTO and access to generics	35
TRIPS patent ruling on least-developed countries, 2002	35
2003 Agreement	36
Original decision turns ten	39
Actavis.....	41
Introduction	41
Company Details	41
Organisational Structure	41
Products.....	42
Own-Label Sales.....	42
Third-Party Sales	42
Hospital Products.....	42
Recent Developments	44
Recent Acquisitions.....	44
Actavis acquires PharmaPack International	44
Recent Company News	44
Actavis plans to launch oncology products in Turkey in the coming year	44
Actavis chief become EGA President; sets out viewpoint	45
Actavis plans Latin America expansion	45
Actavis formally opens Zug headquarters; details market strategy	45
Actavis opens expansion to Iceland manufacturing plant.....	46
EC clears acquisition of control of Actavis by Deutsche Bank.....	46
Actavis plans biosimilars entry with help from Biopartners acquisition.....	46
Recent Litigation	47
Avanir Pharmaceuticals files dextromethorphan + quinidine lawsuit against Actavis and others.....	47
Eli Lilly gains appellate court ruling on atomoxetine patent validity.....	47
Generics industry welcomes Supreme Court ruling regarding labelling	48
Pfizer settles gabapentin litigation with Teva and Actavis	48
Texas jury orders Actavis to pay US\$170 million in damages.....	49
Shire gains lisdexamphetamine exclusivity victory.....	49
Actavis challenges Labopharm's US trazodone patents.....	49
Apotex	50
Introduction	50
Company Details	50
Products.....	51
ApoTriavir	54
Financials	55
Recent Developments	55

Recent Company News	55
<i>Apotex resumes shipments to the US</i>	55
<i>Apotex plans the construction of a new plant in Mexico</i>	55
<i>Apotex sells group of products to AA Pharma</i>	55
Recent Litigation	56
<i>Path cleared for Apotex to launch clopidogrel in Canada</i>	56
<i>Apotex secures Canadian latanoprost litigation victory</i>	56
<i>Acorda Therapeutics loses tizanidine litigation</i>	56
<i>CGPA and Apotex lose data protection challenge</i>	56
<i>Apotex loses in olopatadine lawsuit</i>	57
<i>Pronova BioPharma reaches patent litigation settlement with Apotex</i>	57
<i>Appellate court upholds budesonide injunction against Apotex</i>	58
<i>Mylan to appeal court paroxetine decision</i>	58
<i>Daiichi Sankyo settles cevimeline patent litigation with Apotex</i>	59
Aspen Pharmacare.....	60
Introduction.....	60
Company Details.....	60
Products	61
HIV/AIDS drugs	61
<i>Tenofovir-based ARVs</i>	62
<i>Efavirenz</i>	63
<i>Abacavir</i>	63
<i>South African government ARV tender</i>	63
Financials	63
Recent Developments	64
Recent Company News	64
<i>Prasco to become US distributor for Aspen branded products</i>	64
<i>Aspen acquires Australia's Sigma Pharmaceuticals</i>	64
Aurobindo.....	66
Introduction.....	66
Company Details.....	66
Products	66
Financials	70
Recent Developments	71
Recent Company News	71
<i>Aurobindo joins the Medicines Patent Pool</i>	71
<i>Aurobindo Pharma establishes JV with Russia's Diod</i>	71
<i>Aurobindo receives FDA Warning Letter</i>	72
<i>Aurobindo to divest Chinese subsidiary</i>	72
<i>Aurobindo enters licensing and supply agreements with AstraZeneca</i>	73
Recent Litigation	73
<i>Takeda settles pioglitazone lawsuits</i>	73
<i>Rosuvastatin patent upheld in court</i>	74

Cipla	75
Introduction	75
Company Details	75
Manufacturing facilities	75
Products.....	76
Financials	77
Recent Developments	78
Recent Company News	78
<i>Dr Reddy's enters agreements with Cipla for Russia and Ukraine</i>	<i>78</i>
Recent Litigation	78
<i>Abbott lopinavir / ritonavir patent rejected in India</i>	<i>78</i>
 Dr Reddy's Laboratories	 79
Introduction	79
Company Details	79
Products.....	80
Financials	82
Segment Data	83
Recent Developments	84
Recent Acquisitions.....	84
<i>Dr Reddy's and GlaxoSmithKline enter US penicillin facility sale</i>	<i>84</i>
Recent Company News	84
<i>Dr Reddy's and Fujifilm to establish Japanese generic joint venture</i>	<i>84</i>
<i>Dr Reddy's and JBCP enter into, then terminate, Russian prescription business deal</i>	<i>84</i>
<i>Dr Reddy's Cuernavaca facility received FDA Warning Letter</i>	<i>84</i>
<i>Dr Reddy's affiliate and Valeant form clocortolone collaboration in US.....</i>	<i>85</i>
<i>Dr Reddy's expands R&D centre in Cambridge.....</i>	<i>85</i>
<i>Dr Reddy's signs agreement with Russia's R-Pharm</i>	<i>86</i>
<i>Dr Reddy's enters agreements with Cipla, Vitabiotics, for Russia and Ukraine.....</i>	<i>86</i>
<i>Alchemia and Dr Reddy's expand fondaparinux marketing collaboration.....</i>	<i>86</i>
Recent Litigation	87
<i>Dr Reddy's settles atorvastatin ANDA litigation with Pfizer</i>	<i>87</i>
<i>Pozen claims win in sumatriptan / naproxen sodium litigation cases</i>	<i>87</i>
<i>AstraZeneca and Pozen file naproxen / esomeprazole patent infringement lawsuit against Dr Reddy's.....</i>	<i>87</i>
<i>Dr Reddy's overturns fexofenadine / pseudoephedrine preliminary injunction</i>	<i>88</i>
<i>Takeda settles pioglitazone lawsuits</i>	<i>89</i>
<i>Forest / Merz settle memantine litigation</i>	<i>90</i>
 Egis.....	 91
Introduction	91
Company Details	91
Products.....	92
Financials	93
Regional sales breakdown	94

Hungary	94
Russia and the CIS	94
Central and Eastern Europe	94
Western Europe	94
Recent Developments	95
Recent Company News	95
<i>Egis enters collaboration agreement with Celltrion</i>	95
Hospira	96
Introduction	96
Company Details	96
Project Fuel	97
<i>Shareholders attempt to sue Hospira over Project Fuel</i>	97
Manufacturing facilities	98
Products	98
Product Development	98
<i>Hospira completes Phase I US clinical trial of erythropoietin in renal patients; commences Phase III</i>	99
Financials	100
Results by region	101
Americas	101
EMEA	101
APAC	101
Recent Developments	102
Recent Company News	102
<i>Hospira board authorises US\$1 billion share repurchase programme</i>	102
Impax Laboratories	103
Introduction	103
Company Details	103
Alliance and collaboration agreements	103
<i>Global Division: alliance and collaboration agreements</i>	104
<i>Teva Agreement</i>	104
<i>OTC Partner Alliance Agreements</i>	104
<i>Impax Division: alliance and collaboration agreements</i>	105
Products	105
Financials	107
Sales by division	107
Recent Developments	108
Recent Company News	108
<i>Impax receives FDA warning letter following Hayward site inspection</i>	108
<i>Impax enters commercialisation agreement with Banner Pharmacaps</i>	108
<i>Impax and Perrigo enter development agreement</i>	108
Recent Litigation	108
<i>Impax launches fentanyl patent challenge</i>	108

<i>Impax and Abbott settle choline fenofibrate patent litigation</i>	109
<i>Impax confirms dutasteride+tamsulosin hydrochloride patent challenge</i>	109
<i>Avanir Pharmaceuticals files dextromethorphan+quinidine lawsuits against Actavis, Par, Impax</i>	109
<i>Impax and Daiichi Sankyo, Genzyme, reach colesevelam settlement</i>	110
<i>Impax initiates tolterodine tartrate patent challenge</i>	111
<i>Impax confirms methylphenidate patent challenge</i>	111
<i>Impax challenges oxycodone patents</i>	111
<i>Impax challenges dexlansoprazole patents</i>	111
<i>Impax confirms niacin+simvastatin patent challenge</i>	112
<i>Shire receives guanfacine Paragraph IV notice from Impax; pair clash over Adderall supplies</i>	113
<i>Impax challenges ezetimibe / simvastatin patent</i>	114
<i>Impax and Watson challenge sevelamer patents</i>	114
<i>Impax and Endo settle oxymorphone litigation</i>	115
Krka	116
Introduction	116
Company Details	116
Krka Group development strategy	116
<i>Krka: key strategies and objectives – to 2014</i>	116
<i>Krka: key strategies – to 2014</i>	117
<i>Krka: Group business objectives for 2011</i>	117
Products	117
Marketing authorisations	118
Prescription pharmaceuticals	119
Financials	119
Results by Regions	120
Slovenia	120
South-Eastern Europe	120
Eastern Europe	120
Central Europe	121
Western Europe and Overseas Market	121
Product and Service Groups	122
Recent Developments	122
Recent Company News	122
<i>Krka opens new R&D centre and manufacturing plant</i>	122
Lannett	123
Introduction	123
Company Details	123
Products	124
Financials	125
Recent Developments	127
Recent Company News	127
<i>Lannett reaches cocaine Special Protocol Assessment agreement with the FDA</i>	127
<i>Lannett reports positive facilities inspections</i>	127

Lupin	128
Introduction	128
Company Details	128
Products	129
Financials	131
Recent Developments	132
Recent Acquisitions	132
<i>Lupin acquires I'rom Pharmaceuticals through Japanese subsidiary</i>	132
Recent Company News	132
<i>Eli Lilly and Lupin enter diabetes strategic collaboration</i>	132
<i>Lupin and Medicis enter into joint development agreement</i>	132
<i>Lupin and Natco join forces to commercialise lapatinib product</i>	132
<i>Lupin enters licensing agreement with NeuClone</i>	133
<i>Salix expands rifaximin collaboration with Lupin</i>	133
<i>Lupin signs agreement with Brazil's Farmanguinhos</i>	133
Recent Litigation	134
<i>Shionogi sees success in metformin litigation</i>	134
<i>Lupin and Medicis settle minocycline litigation</i>	134
<i>Flamel files carvedilol lawsuit against Lupin</i>	134
<i>Lupin and Dainippon settle eszopiclone lawsuit</i>	135
<i>Lupin loses levofloxacin patent challenge</i>	135
<i>Warner Chilcott settles oral contraceptive litigation with Lupin</i>	136
<i>Forest / Merz settle memantine litigation</i>	136
<i>Gilead files ranolazine patent lawsuit against Lupin</i>	136
Mylan	137
Introduction	137
Company Details	137
Products	138
Financials	144
Segment Data	145
<i>Generics Segment</i>	145
<i>Specialty Segment</i>	145
Recent Developments	146
Recent Acquisitions	146
<i>Mylan to acquire Pfizer's respiratory delivery platform</i>	146
<i>Mylan acquires Bioniche injectable business</i>	147
Recent Company News	147
<i>Gilead announces new HIV product licensing rights with four Indian firms</i>	147
<i>Bristol-Myers Squibb signs new agreement to expand access to atazanavir in sub-Saharan Africa and India</i>	148
<i>Dey Pharma enters epinephrine deal with Meda</i>	148
<i>Mylan to invest 67 million euros in Hungary</i>	148
Recent Litigation News	148
<i>Mylan launches oral contraceptive patent challenge</i>	148

<i>Warner Chilcott sees setback in doxycycline hyclate litigation</i>	149
<i>Mylan and Novartis settle oestradiol litigation</i>	149
<i>Mylan enters oral contraceptive settlement agreement</i>	150
<i>Mylan announces capecitabine settlement and licence agreement</i>	150
<i>Mylan initiates frovatriptan patent challenge</i>	150
<i>Teva gains favourable claim construction rulings in glatiramer patent litigation</i>	151
<i>Mylan initiates oestradiol transdermal system patent challenge</i>	151
<i>Endo receives lidocaine patch challenge</i>	152
<i>Orion files entacapone patent infringement lawsuit against Mylan</i>	152
<i>Mylan and Pfizer enter atorvastatin settlements</i>	153
<i>Mylan confirms prednisolone patent challenge</i>	153
<i>Mylan to appeal court paroxetine decision</i>	153
<i>Daiichi Sankyo claims court victor against Mylan in olmesartan medoxomil patent litigation</i>	154
<i>Forest / Merz settle memantine litigation</i>	154
Par Pharmaceutical Companies	155
Introduction	155
Company Details	155
Products	155
Financials	158
Segment Data.....	158
Recent Developments	159
Recent Acquisitions.....	159
<i>Par acquires Anchen Pharmaceuticals</i>	159
<i>Par to acquire Edict Pharmaceuticals</i>	160
Recent Company News.....	160
<i>IntelGenx enters development and commercialisation agreement with Par</i>	160
<i>Intellipharma and Par expand agreement</i>	160
<i>Par restructures its branded division</i>	160
<i>Par enters ezetimibe agreement with Glenmark; Glenmark settles litigation with Merck</i>	161
Recent Litigation News.....	161
<i>Par files declaratory judgement to protect right to provide drug information</i>	161
<i>Pozen claims win in sumatriptan / naproxen sodium litigation cases</i>	161
<i>Par reaches settlement in principle over drug pricing lawsuits</i>	162
<i>Pronova files suits against Par and Teva regarding omega-3-acid ethyl esters</i>	162
<i>Par challenges mesalamine patents</i>	162
<i>Rosuvastatin patent upheld in court</i>	162
<i>Appellate court upholds tramadol decision in Par's favour</i>	163
Perrigo	164
Introduction	164
Company Details	164
Products	166
Financials	168
Segment Sales.....	169

Consumer Healthcare	169
Nutritionals	169
Rx Pharmaceuticals	169
API	169
Recent Developments	170
Recent Acquisitions	170
<i>Perrigo acquires Paddock Laboratories</i>	170
Recent Company News	171
<i>Perrigo facility successfully re-inspected</i>	171
<i>Perrigo acquires OTC fexofenadine / pseudoephedrine rights from Teva</i>	172
Recent Litigation News	172
<i>Perrigo challenges testosterone gel patent</i>	172
<i>Perrigo launches olopatadine nasal spray patent challenge</i>	172
<i>Perrigo enters fluticasone litigation settlements</i>	172
<i>Perrigo initiates calcipotriene and betamethasone patent challenge</i>	172
<i>Perrigo settles minoxidil foam litigation</i>	173
<i>Perrigo confirms filing of omeprazole / sodium bicarbonate ANDA, leading to lawsuit</i>	173
<i>Perrigo submits butoconazole nitrate ANDA to FDA; KV files suit</i>	173
<i>Perrigo challenges clobetasol patents</i>	174
Ranbaxy Laboratories	175
Introduction	175
Company Details	175
Acquisition by Daiichi Sankyo	175
Products	176
New Drug Discovery research	176
Pharmaceutical Research (drug products)	177
Chemical Research (active pharmaceutical ingredients)	177
Antiretrovirals	180
Financials	180
Recent Developments	181
Recent Company News	181
<i>Ranbaxy signs consent decree with FDA; document filed in court</i>	181
<i>Ranbaxy to market Daiichi Sankyo's products in Malaysia</i>	182
<i>Ranbaxy extends Daiichi Sankyo's product reach in Italy</i>	182
<i>Daiichi Sankyo and Ranbaxy to expand Hybrid Business Model in Mexico</i>	183
<i>Ranbaxy to decommission New York facility</i>	183
<i>Gilead announces new HIV product licensing rights with four Indian firms</i>	183
<i>Daiichi Sankyo to use Ranbaxy's market in Singapore</i>	183
<i>Ranbaxy enters MoU with Yaroslavl government</i>	184
<i>Sonke reports success in South African antiretroviral tenders</i>	184
<i>Ranbaxy sets up South African manufacturing facility</i>	184
<i>Daiichi Sankyo to use Ranbaxy to market levofloxacin product in Romania, South Africa</i>	184
<i>Ranbaxy's New Drug Discovery Research arm transferred to Daiichi Sankyo</i>	185

Recent Litigation	185
<i>Takeda settles pioglitazone lawsuits</i>	185
Gedeon Richter.....	186
Introduction	186
Company Details	186
Products.....	187
Research and development	187
Female healthcare	187
Financials	191
Markets – pharmaceutical segment	191
<i>Hungary.....</i>	192
<i>International sales.....</i>	192
<i>European Union</i>	193
<i>CIS.....</i>	193
<i>United States</i>	193
Recent Developments	194
Recent Acquisitions.....	194
<i>Gedeon Richter acquires Switzerland's PregLem</i>	194
Recent Company News	194
<i>Stada and Gedeon Richter enter biosimilars co-operation agreement.....</i>	194
<i>Gedeon Richter and European Investment Bank sign credit line contract</i>	195
<i>Gedeon Richter and Watson enter ulipristal agreement.....</i>	195
<i>Gedeon Richter signs biosimilars agreement with Mochida Pharmaceutical</i>	195
<i>Gedeon Richter forms Chinese joint venture</i>	196
<i>Gedeon Richter acquires Grünenthal's oral contraceptive portfolio.....</i>	196
Recent Litigation	196
<i>Gedeon Richter awarded US\$40 million for failed Polpharma bid.....</i>	196
Sandoz	198
Introduction	198
Company Details	198
Products.....	199
<i>Omnitrope gains new US indications.....</i>	203
<i>Sandoz begins phase II trial for rituximab biosimilar</i>	204
<i>Sandoz initiates two Phase III biosimilar trials.....</i>	204
Financials	204
Recent Developments	205
Recent Company News	205
<i>EC opens antitrust proceedings against Johnson & Johnson and Sandoz</i>	205
<i>Sandoz expands US portfolio to include Alcon ophthalmic generics.....</i>	205
<i>Congress sends letters to firms over 2007/08 contaminated heparin incidents</i>	205
<i>Sandoz opens new development centre in New Jersey</i>	206
Recent Litigation	206

<i>Momenta reports enoxaparin preliminary injunction, change in collaboration terms with Sandoz</i>	206
<i>Astellas files Canadian tacrolimus patent lawsuit against Sandoz</i>	207
<i>Shire files lisdexamphetamine patent infringement lawsuits</i>	207
<i>InSite, Merck & Co and Pfizer file patent litigation against Sandoz over azithromycin filing</i>	208
<i>Takeda settles pioglitazone lawsuits</i>	208
<i>Teva enters litigation against Momenta/Sandoz over generic glatiramer</i>	209
Sanofi	210
Introduction	210
Company Details	210
Winthrop Pharmaceuticals	210
<i>France</i>	210
<i>Germany</i>	210
<i>Portugal</i>	211
<i>United Kingdom</i>	211
Zentiva	211
<i>Slovakofarma</i>	211
<i>Léciva</i>	212
Products	212
Financials	212
Recent Developments	213
Recent Company News	213
<i>All European Sanofi generics to be marketed under Zentiva brand name</i>	213
<i>Zentiva plans to enter the generic respiratory medicines segment</i>	213
Sawai Pharmaceutical	214
Introduction	214
Company Details	214
Medium-term Business Plan M1 TRUST	214
Products	215
New government supply rules, 2006	216
Financials	216
Recent Developments	217
Recent Company News	217
<i>Acino and Sawai sign collaboration agreement for Japanese market</i>	217
Simcere Pharmaceutical	218
Introduction	218
Company Details	218
Products	219
Financials	220
Recent Developments	221
Recent Company News	221
<i>Simcere's branded generic diosmectite product passes EU-GMP inspection</i>	221

<i>Merck/Simcere to establish Chinese JV</i>	221
<i>Simcere interest gains Chinese drug approval; Simcere also plans to establish R&D centre</i>	222
<i>Simcere to gain 90% stake in Boda</i>	222
Recent Litigation	222
<i>Simcere reaches agreement with former Jiangsu Quanyi shareholders</i>	222
Stada Arzneimittel	223
Introduction	223
Company Details	223
Build the future	223
Products	224
Biosimilars.....	225
Financials	225
Segment Data	226
Geographic Segment Data	227
<i>Germany</i>	227
<i>Russia</i>	227
<i>Belgium</i>	227
<i>Serbia</i>	227
<i>Italy</i>	227
Recent Developments	229
Recent Acquisitions.....	229
<i>Stada to acquire Spig's generics business</i>	229
<i>Stada acquires branded product portfolio from Grünenthal</i>	229
<i>Stada acquires UK branded product</i>	229
Recent Company News	230
<i>Stada secures 400 million euros of promissory notes</i>	230
<i>Stada welcomes efforts to stabilise Serbian healthcare market</i>	230
<i>Stada and Gedeon Richter enter biosimilars co-operation agreement</i>	231
<i>Stada gains successes in German tenders</i>	231
Sun Pharmaceutical Industries	233
Introduction	233
Company Details	233
Group Companies	233
<i>Caraco Pharmaceutical Laboratories</i>	233
<i>Sun Pharmaceutical Industries (SPI)</i>	234
<i>Sun Pharmaceutical (Bangladesh)</i>	234
<i>Alkaloida Chemical Company Exclusive Group Ltd</i>	234
<i>Chattem Chemicals</i>	235
<i>Taro Pharmaceutical Industries</i>	235
Products	236
Financials	239
Recent Developments	240

Recent Company News	240
<i>MSD and Sun enter strategic partnership in India</i>	240
Recent Litigation News	240
<i>Sun receives oxaliplatin blow</i>	240
<i>Depomed files metformin ER patent lawsuit against Sun</i>	241
<i>Sun sees gemcitabine patent victory against Eli Lilly</i>	241
<i>Nycomed and Pfizer see pantoprazole litigation success</i>	242
<i>Forest / Merz settle memantine litigation</i>	242
Teva Pharmaceutical Industries	243
Introduction	243
Company Details	243
<i>Teva outlines respiratory business growth strategy</i>	244
Organisational structure	244
Products	245
Pharmaceutical Production	245
Raw materials for pharmaceutical production	246
Research and development	246
Generic Products	246
North America	247
Europe	248
International	248
Branded products	248
Copaxone	249
<i>Peptimmune files glatiramer Citizen Petition</i>	249
Azilect	250
Biopharmaceuticals and biosimilars	250
<i>Teva plans further study with rituximab biosimilar</i>	251
Financials	255
Geographical breakdown	255
<i>North America</i>	255
<i>Europe</i>	256
<i>International Markets</i>	256
Sales by product line	256
<i>Generics and Other Products</i>	256
<i>Innovative Products</i>	256
<i>Biosimilars</i>	257
Recent Developments	257
Recent Acquisitions	257
<i>Acino and Teva sign deal to complete acquisition of Mepha businesses</i>	257
<i>Teva completes Cephalon acquisition</i>	258
<i>Teva buys out Kowa's stake in Japanese joint venture</i>	259
<i>Teva completes acquisition of Taiyo</i>	259

<i>Corporación Infarmasa</i>	259
<i>Laboratoire Théramex</i>	259
<i>ratiopharm</i>	260
Recent Company News	260
<i>Teva announces US\$3 billion share repurchase programme</i>	260
<i>Teva announces pricing of US\$5 billion of Senior Notes</i>	261
<i>Teva to construct manufacturing facility in Russia</i>	261
<i>Teva and Procter & Gamble form consumer healthcare partnership</i>	261
<i>APP and Teva enter gemcitabine agreement</i>	262
<i>Teva enters into US\$1.5 billion syndicated credit facility</i>	262
<i>Teva enters agreement for AMD treatment</i>	262
<i>Teva opens a new pharmaceutical packaging plant in Hungary</i>	263
Recent Litigation	263
<i>The Medicines Company settles bivalirudin patent litigation with Teva</i>	263
<i>Teva gains favourable claim construction rulings in glatiramer patent litigation</i>	263
<i>Pfizer claims sildenafil citrate patent victory against Teva</i>	264
<i>Pronova BioPharma provides litigation update</i>	264
<i>Amgen and Teva settle G-CSF patent litigation</i>	264
<i>Teva and Pfizer battle in UK courts over atorvastatin; reach settlement</i>	265
<i>Pfizer settles gabapentin litigation with Teva</i>	266
<i>Cubist settles daptomycin litigation with Teva</i>	266
<i>Watson gains success in oral contraceptive litigation brought by Teva</i>	267
<i>Teva loses cinacalcet patent challenge</i>	267
<i>Takeda settles pioglitazone lawsuits</i>	268
<i>Companies issue aripiprazole appeal</i>	268
<i>Momenta files enoxaparin litigation against Teva</i>	269
<i>Merck claims temozolomide patent lawsuit victory</i>	269
<i>Nycomed and Pfizer see pantoprazole litigation success</i>	270
Watson Pharmaceuticals	271
Introduction	271
Company Details	271
<i>Watson designates Parsippany, New Jersey, as corporate headquarters</i>	271
Arrow.....	271
Andrx.....	272
Operations	272
Products.....	273
Generics.....	274
Brand Products	275
<i>Watson suffers setback as FDA advisory committee declines to approve novel progesterone product</i>	275
Distribution	275
Financials	278
Segment Results.....	278
<i>Global Generic Segment</i>	279
<i>Global Brand Segment</i>	279

<i>Distribution Segment</i>	279
Recent Developments	279
Recent Acquisitions	279
<i>Watson acquires Ascent Pharmahealth</i>	279
<i>Watson acquires the Greek firm, Specifar Pharmaceuticals</i>	280
Recent Company News	281
<i>Amgen and Watson to collaborate on oncology biosimilars</i>	281
<i>Watson subsidiary to build new warehouse and distribution facility</i>	281
<i>Watson and Antares enter into oxybutynin gel product agreement</i>	281
<i>Watson expands Salt Lake City facility</i>	282
<i>FTC claims sanofi-aventis, Watson and Synthron failed to report drug patent agreements</i>	282
<i>Watson and Natco enter lenalidomide agreement</i>	283
<i>Gedeon Richter and Watson enter ulipristal agreement</i>	283
<i>Watson signs authorised generic agreement with Ortho-McNeil-Janssen Pharmaceuticals</i>	283
<i>Watson and Moksha8 form marketing partnership for Brazil and Mexico</i>	284
<i>Watson enters biosimilar product development agreement with Itero</i>	284
<i>Watson completes acquisition of Crinone/Prochieve and Columbia shares</i>	284
Recent Litigation News	285
<i>Mylan confirms pioglitazone + metformin patent challenge</i>	285
<i>Watson confirms rivastigmine patent challenge</i>	285
<i>Watson claims victory in oral contraceptive litigation</i>	286
<i>Watson confirms risedronate patent challenge</i>	286
<i>Noven files methylphenidate litigation</i>	286
<i>Watson initiates morphine / naltrexone patent challenge</i>	287
<i>Watson confirms dutasteride and tamsulosin patent challenge</i>	287
<i>Watson claims victory in guaifenesin patent battle</i>	288
<i>Shire files lisdexamphetamine patent infringement lawsuits</i>	288
<i>Watson confirms dutasteride patent challenge</i>	288
<i>Watson challenges olopatadine patents</i>	289
<i>Watson initiates sildenafil patent challenge</i>	289
<i>Watson initiates second colesevelam patent challenge</i>	289
<i>Watson confirms moxifloxacin hydrochloride patent challenge</i>	290
<i>Shire files Adderall patent infringement and breach of contract lawsuit against Watson</i>	290
<i>Watson receives blow in fentanyl buccal tablet litigation</i>	291
<i>Watson gains success in oral contraceptive litigation brought by Teva</i>	291
<i>Watson confirms oxycodone challenge</i>	292
<i>Takeda settles pioglitazone lawsuits</i>	292
<i>Watson confirms hydromorphone hydrochloride patent challenge</i>	293
<i>Shire files more guanfacine lawsuits</i>	293
<i>Watson challenges rosuvastatin patents</i>	293
<i>Watson confirms rasagiline patent challenge</i>	294
<i>Watson settles oxymorphone litigation with Endo</i>	294
<i>Watson confirms brimonidine tartrate and timolol maleate ophthalmic patent challenge</i>	295
<i>Forest / Merz settle memantine litigation</i>	295
<i>Impax and Watson challenge sevelamer patents</i>	295

Wockhardt.....	297
Introduction	297
Company Details	297
Products.....	299
Financials	301
Recent Developments	302
Recent Company News	302
<i>Wockhardt signs recombinant insulin agreement with Sheffield Bio-Science</i>	<i>302</i>
Recent Litigation News	302
<i>Eli Lilly wins duloxetine patent litigation.....</i>	<i>302</i>
<i>Takeda settles pioglitazone lawsuits</i>	<i>303</i>
<i>Forest / Merz settle memantine litigation</i>	<i>303</i>
Zydus Cadila	304
Introduction	304
Company Details	304
Products.....	305
Financials	307
Recent Developments	308
Recent Acquisitions.....	308
<i>Zydus Cadila acquires Biochem</i>	<i>308</i>
<i>Zydus acquires KV's generics business</i>	<i>308</i>
Recent Company News	309
<i>Microbix and Zydus Cadila reach urokinase agreement for North America.....</i>	<i>309</i>
<i>Bayer and Zydus create joint venture in India.....</i>	<i>309</i>
<i>Zydus Nycomed commissions newly-expanded plant.....</i>	<i>310</i>
Recent Litigation News	310
<i>Mesalamine lawsuit filed against Zydus Cadila</i>	<i>310</i>